BridgeBio Pharma Inc (NASDAQ:BBIO)’s traded shares stood at 0.61 million during the latest session, with the company’s beta value hitting 1.08. At the last check today, the stock’s price was $34.35, to imply an increase of 2.68% or $0.9 in intraday trading. The BBIO share’s 52-week high remains $39.47, putting it -14.91% down since that peak but still an impressive 37.06% since price per share fell to its 52-week low of $21.62.
Analysts have given a consensus recommendation of Buy for BridgeBio Pharma Inc (BBIO), translating to a mean rating of 1.38. Of 9 analyst(s) looking at the stock, 0 analyst(s) give BBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 9 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.86.
BridgeBio Pharma Inc (NASDAQ:BBIO) trade information
After registering a 2.68% upside in the latest session, BridgeBio Pharma Inc (BBIO) has traded red over the past five days. The 5-day price performance for the stock is -6.68%, and -5.41% over 30 days. With these gigs, the year-to-date price performance is 25.16%.
The extremes give us $45 and $53 for target low and target high price respectively. As such, BBIO has been trading -54.29% off suggested target high and -31.0% from its likely low.
BridgeBio Pharma Inc (BBIO) estimates and forecasts
The rating firms project that company’s revenue will shrink -6.25% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 56.25M. Meanwhile, for the current quarter, a total of 10 analyst(s) estimate revenue growth to 43.31M.Earnings reports from the last fiscal year show that sales brought in 211.12M and 2.17M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -73.36% before jumping 1,897.82% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -3.04% for the past 5-year period. While 2025 is set for a -29.93% return in earnings, projections for the next 5 years are at 42.31% annually.
BBIO Dividends
BridgeBio Pharma Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is VIKING GLOBAL INVESTORS LP with 25.12 million shares, or about 13.3917% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $636.31 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the BridgeBio Pharma Inc (BBIO) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 4.53 shares. This is just over 2.38% of the total shares, with a market valuation of $155.49 million. Data from the same date shows that the other fund manager holds a little less at 3.93, or 2.07% of the shares, all valued at about 134.9 million.
